Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.49 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.43 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699035 | 0.94 | MAP4K4 (0.48) | MAP4K4TRPV3EIF2AK4PDE10APSEN1 | |
| SCHEMBL17778379 | 0.91 | MAP4K4 (0.49) | MAP4K4TRPV3EIF2AK4PDE10APSEN1 | |
| SCHEMBL20632886 | 0.91 | MAP4K4 (0.49) | MAP4K4TRPV3EIF2AK4PDE10APSEN1 | |
| SCHEMBL16237499 | 0.91 | MAP4K4 (0.49) | MAP4K4TRPV3EIF2AK4PDE10APSEN1 | |
| SCHEMBL16249992 | 0.91 | MAP4K4 (0.49) | MAP4K4TRPV3EIF2AK4PDE10APSEN1 | |
| SCHEMBL17778528 | 0.89 | MAP4K4 (0.46) | MAP4K4TRPV3EIF2AK4PDE10APSEN1 | |
| SCHEMBL16754566 | 0.89 | MAP4K4 (0.46) | MAP4K4TRPV3EIF2AK4PDE10APSEN1 | |
| SCHEMBL16754630 | 0.88 | MAP4K4 (0.47) | MAP4K4TRPV3EIF2AK4PDE10AHRH3 | |
| SCHEMBL16776499 | 0.83 | MAP4K4 (0.45) | MAP4K4TRPV3EIF2AK4PDE10APSEN1 | |
| SCHEMBL16776503 | 0.83 | MAP4K4 (0.45) | MAP4K4TRPV3EIF2AK4PDE10APSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MAP4K4 1867/4885TRPV3 4464/4885EIF2AK4 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.